Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient

Abstract A 62-year-old patient had characteristics corresponding to the diagnostic criteria of medication-related osteonecrosis of the jaw (MRONJ). She had been treated for renal cell carcinoma with radical nephrectomy and chemotherapy with pazopanib (Votrient® ) and everolimus (Afinitor® ) antiangi...

Full description

Saved in:
Bibliographic Details
Published inOral and maxillofacial surgery cases Vol. 3; no. 2; pp. 27 - 33
Main Author Jung, Tae-Young, DDS, PhD
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.06.2017
Elsevier
Subjects
Antiangiogenic agents
Medication-related osteonecrosis of the jaw
Renal cell carcinoma
Surgery
Medication-related osteonecrosis of the jaw
Renal cell carcinoma
Antiangiogenic agents
Online AccessGet full text

Cover

More Information
Summary:Abstract A 62-year-old patient had characteristics corresponding to the diagnostic criteria of medication-related osteonecrosis of the jaw (MRONJ). She had been treated for renal cell carcinoma with radical nephrectomy and chemotherapy with pazopanib (Votrient® ) and everolimus (Afinitor® ) antiangiogenic agents. There was no history of radiation therapy, obvious metastatic disease or surgical treatment. Bone exposure was observed in both mandibular posterior regions. Bone necrosis had developed surrounding the #35=37 and 46, 47 implants installed 6 years prior. The lesions were diagnosed as MRONJ and the patient was treated by sequestrectomy, saucerization and reconstruction with a reconstruction plate. The clinical results were good.
ISSN:2214-5419
2214-5419
DOI:10.1016/j.omsc.2017.03.001